The efficacy and safety of DW1601 in patients with acute bronchitis: a multi-center, randomized, double-blind, phase III clinical trial.
- 2022-09-26
- RCT · n = 204
- The Korean journal of internal medicine 37(6)
- Young Seok Lee
- Seong Yong Lim
- Kyung Hoon Min
- Do Jin Kim
- Kwang Ha Yoo
- Tae-Bum Kim
- Hak-Ryul Kim
- Jae Jeong Shim
- PubMed: 36153858
- DOI: 10.3904/kjim.2022.104
- High evidence
- Large Human Trial
- Clinical
Participants treated with DW1601 showed higher rates of response and satisfaction than control groups (response rate, DW1601, 100% vs. DW16011, 85.7% vs. P. sidoides, 85.9%
- Effect
- Neutral
- Effect size
- Small
- Significant
- No